Northland Securities Expects Stronger Earnings for Nephros

Nephros Inc. (NASDAQ:NEPH) – Equities researchers at Northland Securities upped their Q3 2026 earnings per share (EPS) estimates for shares of Nephros in a research report issued on Thursday, August 13th. Northland Securities analyst B. Brooks now anticipates that the company will earn $0.02 per share for the quarter, up from their prior forecast of $0.01. Northland Securities currently has a “Market Perform” rating and a $4.00 price target on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.15 per share. Northland Securities also issued estimates for Nephros’ FY2026 earnings at $0.15 EPS, Q2 2027 earnings at $0.17 EPS and FY2027 earnings at $0.31 EPS.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $6.02 million for the quarter, compared to the consensus estimate of $4.99 million. Nephros had a return on equity of 10.60% and a net margin of 8.38%.

Other research analysts also recently issued research reports about the stock. Weiss Ratings raised shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. Zacks Research raised shares of Nephros to a “hold” rating in a research report on Monday, July 20th. Finally, Benchmark restated a “speculative buy” rating on shares of Nephros in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nephros Stock Performance

NEPH stock opened at $4.59 on Monday. Nephros has a one year low of $2.66 and a one year high of $6.42. The firm has a market cap of $49.85 million, a price-to-earnings ratio of 28.69 and a beta of 1.51. The firm has a 50-day simple moving average of $3.61 and a two-hundred day simple moving average of $3.51.

Institutional Investors Weigh In On Nephros

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC purchased a new stake in shares of Nephros during the fourth quarter worth about $29,000. Dimensional Fund Advisors LP raised its position in shares of Nephros by 52.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after purchasing an additional 7,144 shares during the last quarter. De Lisle Partners LLP acquired a new stake in Nephros in the 2nd quarter worth approximately $62,000. Heron Bay Capital Management acquired a new stake in Nephros in the 4th quarter worth approximately $66,000. Finally, BlackRock Inc. purchased a new stake in Nephros during the 2nd quarter worth approximately $67,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.